Metoprolol succinate is indicated for hypertension, angina pectoris, and heart failure. It functions as a beta-1 selective adrenergic receptor blocking agent, slowing the sinus rate and decreasing AV nodal conduction. The mechanism of action in hypertension is not fully understood, but it involves competitive antagonism of catecholamines and potentially central effects.
Key Clinical Findings
In angina, it reduces oxygen requirements of the heart by blocking catecholamine-induced increases in heart rate, myocardial contraction, and blood pressure. In heart failure, it reduces the risk of cardiovascular mortality and heart failure hospitalizations. Clinical studies demonstrate that metoprolol succinate extended-release tablets, administered once daily, effectively lowers sitting blood pressure (6-8/4-7 mmHg) and reduces the number of angina attacks. A double-blind study involving 1,092 patients with mild-to-moderate hypertension showed that metoprolol succinate extended-release tablets alone decreased sitting blood pressure. The starting dose for hypertension is 25-100 mg, titrated as needed. For angina, the starting dose is 100 mg. In heart failure, the starting dose is 12.5 or 25 mg. Plasma concentrations of metoprolol correlate with the degree of beta-1 blockade, with effects ranging from 30 to 80% of the maximal effect at concentrations from 30 to 540 nmol/L.